The information contained in this page is intended for U.S. healthcare professionals only.
On this page:
Bringing About Personalized Innovation in Hemophilia Treatment
Thanks in part to hemophilia therapies currently available, life expectancy for hemophilia patients has increased on average to more than 60 years today.1 Baxter is committed to actively listening to and working with the hemophilia community to proactively shape the future of hemophilia by focusing on personalized innovations and solutions.
Baxter's range of management options allows clinicians to choose the appropriate product based on individual patient needs.
Specifically, Baxter is:
- Supporting advocacy through community participation, including through patient and clinician education and expanding patient access to therapy
- Advancing its portfolio through new therapies to address unmet market needs
To help ensure a thriving community of hemophilia researchers and clinicians, Baxter recognizes the importance of supporting and promoting those currently working in the field and future leaders, including support through the funding of grants and fellowship programs in hemophilia and coagulation disorders. These programs include:
- NHF Clinical Fellowship Program in Bleeding Disorders Research
- Training in Bleeding Disorders for Healthcare Providers - A CDC training program for providers in Treatment Centers
- Provider Shadow Program (at Rush University Medical Center in Chicago)
- Sponsorship of Continued Medical Education (CME)
Our commitment to care continues through grants that support the creation of independent educational programs and symposia.